Platelet transfusion does not improve outcomes in patients with brain injury on antiplatelet therapy.
Jeremy L Holzmacher, Cassandra Reynolds, Mayur Patel...
https://pubmed.ncbi.nlm.nih.gov/29341793/Actively Recruiting
Led by Beijing Tiantan Hospital · Updated on 2026-07-10
2000
Participants Needed
1
Research Sites
52 weeks
Total Duration
Researchers are studying patients with severe spontaneous intracerebral hemorrhage SSICH, a type of brain bleeding, focusing on those who are on long-term oral antiplatelet therapy LOAPT. The study aims to evaluate how emergency surgery compares to standard conservative treatment in terms of survival and safety. This registry study, called CRISIH, is ongoing and gathers data from multiple centers in China over a planned 10-year period starting in 2019, with a special interest in surgical outcomes and complications for these patients. Participants receive either emergency neurosurgery to evacuate the brain hemorrhage or conservative treatments as determined by routine clinical practice. The registry collects detailed clinical, radiological, surgical, and laboratory information about each patient. Follow-up includes assessments up to six months post-hemorrhage for mortality, as well as monitoring for surgical complications and disorders of consciousness at multiple time points post-surgery. During the study, participants health data are regularly recorded, including postoperative bleeding events and consciousness status measured by the Coma Recovery Scale-Revised at 30, 90, 180, and 365 days after surgery. The main outcome measured is total mortality from hospital admission through six months after the initial hemorrhage. The study continues to enroll and follow patients beyond the initial five years, with ongoing data collection to enhance understanding of treatment effects and safety.
CONDITIONS
China Research for Severe Spontaneous Intracerebral Hemorrhage(CRISIH)
S
Shuo Wang
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Beijing Tiantan Hospital
Lead Sponsor
Beijing Chao Yang Hospital
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 6 months after hemorrhage occurrence
Participants receive surgical or conservative treatment based on clinical decisions and are followed for outcomes including survival, postoperative bleeding, and consciousness recovery. Data collection includes clinical, radiological, surgical, and laboratory information.
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Have more questions? Get in touch with our team for quick support
Jeremy L Holzmacher, Cassandra Reynolds, Mayur Patel...
https://pubmed.ncbi.nlm.nih.gov/29341793/Yuqian Li, Ruixin Yang, Zhihong Li...
https://pubmed.ncbi.nlm.nih.gov/28578111/Todd H Baron, Patrick S Kamath, Robert D McBane
https://pubmed.ncbi.nlm.nih.gov/23718166/K Krittalak, K Sawanyawisuth, S Tiamkao
https://pubmed.ncbi.nlm.nih.gov/22435901/R J Luddington
https://pubmed.ncbi.nlm.nih.gov/15784122/Kah Fang Khoo, Bayan Lepas
https://pubmed.ncbi.nlm.nih.gov/24379098/Andrew M Naidech, Borko Jovanovic, Storm Liebling...
https://pubmed.ncbi.nlm.nih.gov/19443791/James D Douketis, Ebtisam Bakhsh
https://pubmed.ncbi.nlm.nih.gov/18575419/Charlotte Cordonnier, Andrew Demchuk, Wendy Ziai...
https://pubmed.ncbi.nlm.nih.gov/30319113/M C Korinth
https://pubmed.ncbi.nlm.nih.gov/16969624/Beijing Tiantan Hospital
Lead Sponsor
Beijing Chao Yang Hospital
Collaborating Sponsor